These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal? Wolters LM; Niesters HG; de Man RA; Schalm SW Antiviral Res; 1999 May; 42(1):71-6. PubMed ID: 10333144 [TBL] [Abstract][Full Text] [Related]
25. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. Treviño A; Soriano V; Madejon A; Rodriguez C; Barros C; Botecchia M; Tuma P; Del Romero J; de Mendoza C AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1273-6. PubMed ID: 20001517 [TBL] [Abstract][Full Text] [Related]
26. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ; J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786 [TBL] [Abstract][Full Text] [Related]
28. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. Thio CL; Smeaton L; Hollabaugh K; Saulynas M; Hwang H; Saravanan S; Kulkarni S; Hakim J; Nyirenda M; Iqbal HS; Lalloo UG; Campbell TB; Lockman S; Currier JS AIDS; 2015 Jun; 29(10):1173-82. PubMed ID: 26035319 [TBL] [Abstract][Full Text] [Related]
29. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy. Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813 [TBL] [Abstract][Full Text] [Related]
30. Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy. Calisti G; Muhindo R; Boum Y; Wilson LA; Foster GM; Geretti AM; Bhagani S Trans R Soc Trop Med Hyg; 2015 Nov; 109(11):723-9. PubMed ID: 26386408 [TBL] [Abstract][Full Text] [Related]
31. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans. Lukhwareni A; Gededzha MP; Amponsah-Dacosta E; Blackard JT; Burnett RJ; Selabe SG; Kyaw T; Mphahlele MJ Viruses; 2020 Jun; 12(6):. PubMed ID: 32545313 [TBL] [Abstract][Full Text] [Related]
32. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells]. Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052 [TBL] [Abstract][Full Text] [Related]
33. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Martin-Carbonero L; Soriano V J Antimicrob Chemother; 2010 Mar; 65(3):379-82. PubMed ID: 20085999 [TBL] [Abstract][Full Text] [Related]
35. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567 [TBL] [Abstract][Full Text] [Related]
36. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. Núñez M; Pérez-Olmeda M; Díaz B; Ríos P; González-Lahoz J; Soriano V AIDS; 2002 Nov; 16(17):2352-4. PubMed ID: 12441815 [TBL] [Abstract][Full Text] [Related]
37. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients. Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172 [TBL] [Abstract][Full Text] [Related]
38. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608 [TBL] [Abstract][Full Text] [Related]
39. HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. Audsley J; Littlejohn M; Yuen L; Sasadeusz J; Ayres A; Desmond C; Spelman T; Lau G; Matthews GV; Avihingsanon A; Seaberg E; Philp F; Saulynas M; Ruxrungtham K; Dore GJ; Locarnini SA; Thio CL; Lewin SR; Revill PA Virology; 2010 Sep; 405(2):539-47. PubMed ID: 20655563 [TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Vig P; Gibbs CS; Brosgart C; Fry J; Namini H; Katlama C; Poynard T Lancet; 2001 Sep; 358(9283):718-23. PubMed ID: 11551579 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]